

SCIENTIFIC REPORTS



OPEN

Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells

Received: 22 November 2016

Accepted: 27 March 2017

Published: 24 April 2017

James R. C. Miller¹, Edith L. Pfister², Wanzhao Liu², Ralph Andre¹, Ulrike Träger^{1,†}, Lori A. Kennington², Kimberly Lo³, Sipke Dijkstra³, Douglas Macdonald⁴, Gary Ostroff⁵, Neil Aronin² & Sarah J. Tabrizi¹

Post-transcriptional gene silencing is a promising therapy for the monogenic, autosomal dominant, Huntington's disease (HD). However, wild-type huntingtin (HTT) has important cellular functions, so the ideal strategy would selectively lower mutant HTT while sparing wild-type. HD patients were genotyped for heterozygosity at three SNP sites, before phasing each SNP allele to wild-type or mutant *HTT*. Primary *ex vivo* myeloid cells were isolated from heterozygous patients and transfected with SNP-targeted siRNA, using glucan particles taken up by phagocytosis. Highly selective mRNA knockdown was achieved when targeting each allele of rs362331 in exon 50 of the *HTT* transcript; this selectivity was also present on protein studies. However, similar selectivity was not observed when targeting rs362273 or rs362307. Furthermore, HD myeloid cells are hyper-reactive compared to control. Allele-selective suppression of either wild-type or mutant HTT produced a significant, equivalent reduction in the cytokine response of HD myeloid cells to LPS, suggesting that wild-type HTT has a novel immune function. We demonstrate a sequential therapeutic process comprising genotyping and mutant *HTT*-linkage of SNPs, followed by personalised allele-selective suppression in a small patient cohort. We further show that allele-selectivity in *ex vivo* patient cells is highly SNP-dependent, with implications for clinical trial target selection.

Huntington's disease (HD) is a fatal, autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (*HTT*) gene¹. Production of the mutant (m)HTT protein is the primary cause of pathology, and numerous studies have demonstrated that lowering cellular levels of mHTT using siRNA or antisense oligonucleotides is beneficial in animal models^{2–4}. Most studies have utilised non-selective suppression of both mHTT and wild-type HTT, whereby the target nucleotide sequence is present on both *HTT* alleles. However, wild-type HTT has important roles in cellular function¹, and although preclinical data suggests that partial lowering of wild-type HTT is tolerated in the adult brain^{4–6}, intuitively the optimal strategy would selectively lower mHTT while sparing wild-type.

Allele-selective suppression may be achieved by genotyping HD patients to identify heterozygous single nucleotide polymorphisms (SNPs) in the *HTT* gene, before delivering siRNA specific for the SNP allele that is mHTT-associated⁷. Genotyping studies have suggested that 75% of Caucasian HD gene carriers would be treatable with five siRNAs targeting three SNPs⁸, and SNP-targeting strategies have been used successfully in human fibroblast and stem cell lines, as well as in transgenic mouse models of HD^{9–11}. However, allele-selective suppression of mHTT has not yet been demonstrated in easily accessible primary *ex vivo* HD patient cells, with samples taken from a cohort of patients whose genotype was not known *a priori*. Carrying out a sequential workflow comprising personalised genotyping and mHTT suppression is key to determining the practical relevance of this approach, and has relevance to future potential HD clinical trials aimed at lowering mHTT.

¹Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, WC1N 3BG, UK. ²RNA Therapeutics Institute and Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA. ³Charles River, Leiden, The Netherlands. ⁴CHDI Management/CHDI Foundation, Los Angeles, CA, USA. ⁵Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA. [†]Present address: Immune Tolerance, Tumor Immunology Program, German Cancer Research Center, 69120 Heidelberg, Germany. Correspondence and requests for materials should be addressed to S.J.T. (email: s.tabrizi@ucl.ac.uk)

Results

Allele-selective *HTT* suppression in HD patient cells using siRNA targeted to rs362331. We utilised siRNAs designed against the SNPs rs362331 in exon 50 (39.4% heterozygous C/T), rs362273 in exon 57 (35.2% heterozygous A/G) and rs362307 in the 3'-UTR (48.6% heterozygous C/T) of the *HTT* transcript. The siRNAs targeted to rs362273 and rs362307 have previously demonstrated good selectivity using luciferase assays in HeLa cells⁸. However, the siRNAs designed against rs362331 have not been previously published. As the T allele of rs362307 is linked to *mHTT*⁸, testing siRNA targeting the C allele was unnecessary. Diagnostic DNA samples were analysed to determine individual SNP genotypes for a cohort of HD patients; we identified fifty-seven individuals who were heterozygous for rs362331, thirty-eight who were heterozygous for rs362273 and fifty-four who were heterozygous for rs362307. Monocyte-derived macrophages were then isolated from repeat peripheral blood samples donated by a subset of the heterozygous individuals. Transfection was carried out using glucan-encapsulated siRNA particles (GeRPs), which are taken up by phagocytosis before releasing their siRNA contents into the cytoplasm of the target cell. Cultures were harvested 72 h after transfection and mRNA expression was analysed by allele-specific qPCR. Previously validated non-selective anti-total *HTT* siRNA was used as a positive control¹².

Targeting rs362331 with anti-U siRNA resulted in 74% on-target U allele suppression, compared to 17% off-target C allele suppression (Fig. 1a). Targeting this SNP with anti-C siRNA resulted in 63% on-target suppression, with 30% off-target suppression. Post-hoc testing revealed the discrimination between alleles to be significant for each siRNA ($p < 0.05$). Indeed, in both cases on-target knockdown was equivalent to non-selective siRNA, while off-target knockdown was not statistically significant compared to nonsense control.

Unfortunately, comparable selectivity was not achieved when testing siRNAs targeted to either rs362273 or rs362307 (Fig. 1b,c). Although post-hoc testing demonstrated statistically significant allelic discrimination following treatment with the rs362273 anti-G siRNA, mean off-target knockdown of this degree is clearly too great to consider the particular siRNAs to be truly selective. These data are consistent with the poor discrimination previously seen when testing siRNA against rs362307 in cell lines and animal models^{11,13}.

Selective suppression of *mHTT* protein in HD patient cells using siRNA targeted to rs362331. We next validated that total (polyQ-independent) and *mHTT* (polyQ-expanded) protein levels were similarly reduced; analysis was again carried out 72 h after transfection with siRNAs targeted to either allele of rs362331. As the siRNAs targeted to rs362273 and rs362307 did not achieve significant mRNA selectivity, it was decided not to advance their use to protein studies. To determine which siRNA was targeting *mHTT*, each patient's SNP alleles were linked to either wild-type or *mHTT* using the SNP linkage by circularization technique¹²; the T allele of rs362331 was located on the *mHTT* allele in each subject used for protein analysis. As expected, we observed equivalent suppression of total *HTT* following treatment with each allele-selective siRNA, demonstrating that their effects on total *HTT* levels are independent of *mHTT*-linkage (Fig. 2a). However, we only observed significant suppression of *mHTT* compared to nonsense control with *mHTT*-targeted anti-U siRNA, with no significant reduction in *mHTT* following treatment with wild-type targeted anti-C siRNA (Fig. 2b). This result shows that the selectivity seen when targeting mRNA at rs362331 also affects the protein level.

Allele-selective suppression of wild-type and *mHTT* reverses the hyper-reactive phenotype of human HD myeloid cells. Previous work has shown that HD myeloid cells are hyper-reactive compared to control cells in response to stimulation with LPS and IFN γ ¹⁴. This phenotype was found to be reversible following non-selective *HTT* suppression with siRNA. To address whether allele-selective suppression has similar effects, we stimulated monocyte-derived macrophages with LPS and IFN γ 72 h after treatment with allele-selective GeRPs targeting either allele of rs362331. Production of IL-6, IL-8 and TNF α was measured 24 h later. Since we observed no significant differences between the mRNA knockdown provided by the anti-U and anti-C siRNAs, the samples were grouped for analysis into anti-wild-type and anti-*mHTT* following SNP linkage to *mHTT*. Interestingly, allele-selective suppression of either wild-type or *mHTT* produced a significant reduction in the levels of each cytokine compared to nonsense control (Fig. 3). No differences in cytokine production were found when selectively suppressing mutant compared to wild-type *HTT*.

Discussion

We demonstrate the first example of a complete sequential workflow comprising SNP genotyping, SNP linkage, and personalised allele-selective suppression with phenotypic reversal of an HD-related cellular deficit in heterozygous primary *ex vivo* patient cells. We achieved this through repeated sampling of a small patient cohort, using siRNA targeted to rs362331 in exon 50 of the *HTT* gene. These genotyping techniques would form the basis of allele-selective treatment in the clinic, and our study demonstrates their first use in combination, instead of individually as part of a technical study^{8,15}. Indeed, blood cells are likely to be used for genotyping in clinical trials due to their easy accessibility, and provide a convenient screening tool for novel therapeutics. Although we saw reduced suppression of protein relative to mRNA, we consider this is likely due to the longer protein half-life allowing more pre-existing species to persist up to 72 h.

These data reinforce previous studies demonstrating that the potency and selectivity of *mHTT* suppression varies considerably depending on the SNP being targeted^{9,11}. While we observed significant allele-selectivity using siRNAs targeted to both alleles of rs362331, we did not see similar effects when targeting either rs362273 or rs362307; this is likely due to additional factors including the nucleotide sequence and tertiary structure of the transcript surrounding the base mismatch. rs362307 is a particularly challenging target for allele-selective suppression as the surrounding sequence is extremely GC rich, with the SNP comprising a pyrimidine mismatch (purine mismatches typically confer greater selectivity)⁷. Indeed, this SNP has now demonstrated poor selectivity across multiple research groups and studies^{11,13}. While previous work has shown that adding an additional




Figure 1. Characterisation of allele-selective siRNAs targeted to three SNPs in heterozygous human HD patient cells. Monocyte-derived macrophages were isolated from SNP-genotyped HD patients and treated with GeRPs containing either nonsense, anti-total *HTT* or allele-selective siRNA targeted to (a) rs362331 in exon 50, (b) rs362273 in exon 57 or (c) rs362307 in the 3'-UTR of the *HTT* transcript. Expression of each SNP allele was then measured 72 h later by qPCR. Data show mean expression of each SNP allele \pm SEM ($n = 3$ for rs362331, $n = 4$ for rs362273 and rs362307), statistical analysis carried out using two-way ANOVA with Bonferroni post-tests. Asterisks above the horizontal line at the top of each graph show significance on ANOVA across the whole experiment before post-hoc testing. Asterisks above individual bars represent post-test significance for the mRNA expression of that allele compared to the same allele in the nonsense-treated samples. Asterisks above horizontal lines between two bars denote allele expression differences within the same treatment on post-hoc testing. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. N = individual biological repeats.




Figure 2. Selective suppression of mHTT protein in human HD patient cells using siRNA targeted to rs362331. Monocyte-derived macrophages were isolated from HD patients heterozygous for rs362331 with linkage of the T allele to mHTT, before treating with GeRPs containing either nonsense, anti-total *HTT* or allele-selective siRNA targeted to each allele of rs362331. Expression of (a) total and (b) mutant *HTT* protein was measured after 72 h using MSD assays, before normalisation to total cellular protein content as measured by BCA assays. Data show mean protein levels \pm SEM ($n = 5$), statistical analysis carried out using one-way ANOVA with Tukey post-hoc testing. Asterisks above the horizontal line at the top of each graph show significance on ANOVA across the whole experiment before post-hoc testing. Asterisks above bars show post-test significance for each siRNA compared to the nonsense-treated samples. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. N = individual biological repeats.

base mismatch in the siRNA sequence can improve selectivity (often at the cost of reduced potency)⁸, the results seen with our anti-rs362307 siRNA suggest that the benefits of this approach may be limited. These data further demonstrate the importance of testing potential therapeutics in primary patient cells containing endogenous expression of full-length *HTT*, as these siRNAs achieved promising selectivity during preliminary testing with a short construct attached to a luciferase reporter⁸.

We further utilised allele-selective suppression to investigate the cytokine response of HD myeloid cells. HD myeloid cells produce increased levels of proinflammatory cytokines compared to control following stimulation with LPS¹⁴. This phenotype is due to an exaggerated NF κ B signalling response caused by a direct interaction of mHTT with IKK, a key cytoplasmic regulator of NF κ B¹⁶. NF κ B signalling has recently been shown to be upregulated even in resting HD myeloid cells, and contributes to an abnormal proinflammatory transcriptional profile in the absence of any stimulation¹⁷. However, very little is known about whether wild-type *HTT* also has a role in innate immune function. If *HTT*'s effects on cytokine production were limited exclusively to the mutant form, it would be expected that selective mHTT-lowering would reduce cytokine production more than selective wild-type lowering. However, we saw no significant differences in cytokine production between the allele-selective treatment groups. These results suggest that wild-type *HTT* has an as yet undefined role in normal immune cell function, and is consistent with previous work showing that cytokine production by control myeloid cells is also reduced following *HTT*-lowering¹⁴. Although none of the differences reached statistical significance, the mean IL-6 and TNF α levels measured following total *HTT*-lowering were less than 50% of those




Figure 3. Allele-selective suppression of wild-type and mHTT reverses the hyper-reactive phenotype of human HD myeloid cells. Monocyte-derived macrophages were isolated from SNP-genotyped HD patients and treated with GeRPs containing either nonsense, anti-total *HTT* or allele-selective siRNA targeted to each allele of rs362331. Linkage of each SNP allele to either wild-type or mHTT was determined using the SNP linkage by circularization protocol. After 72 h the macrophages were stimulated with LPS and IFN γ , before the culture supernatants were collected after a further 24 h and analysed using MSD assays. Cytokine values were normalised to total protein content as measured by BCA assays. Data show mean cytokine levels \pm SEM ($n = 5$ for IL-6 and TNF α , $n = 4$ for IL-8), statistical analysis carried out using one-way ANOVA with Tukey post-hoc testing. Asterisks above the horizontal line at the top of each graph show significance on ANOVA across the whole experiment before post-hoc testing. Asterisks above bars show post-test significance for each siRNA compared to the nonsense-treated samples. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. N = individual biological repeats.

measured following selective lowering of either the mutant or wild-type allele. This result suggests that total cellular *HTT* load may be an important factor influencing cytokine production, as the sparing of one allele by the allele-selective siRNAs will result in less overall knockdown than that achieved by anti-total *HTT* siRNA. However, a full investigation of this hypothesis is beyond the scope of this study.

Finally, as rs362307 is the most prevalent SNP in Caucasian HD patients with 48.6% heterozygosity⁸, it should not be assumed that the optimal SNPs will be targetable when estimating what percentage of HD patients may benefit from allele-selective therapeutics. As a result, it may be necessary to target less prevalent SNPs to improve selectivity, with a subsequent reduction in the treatable proportion of the HD patient population. Non-selective therapeutics are therefore likely to be used to treat the majority of adult HD patients, as partial HTT-lowering has been shown to be well tolerated in the mature brain^{4,5}. However, the deleterious effects associated with *HTT* knockout in the developing brain⁶ suggest that an allele-selective strategy may be more useful for treating pre-symptomatic young adults. We demonstrate that rs362331 may be a promising candidate for this approach.

Methods

Collection and genotyping of human samples. Experiments were performed in accordance with the Declaration of Helsinki and approved by the University College London (UCL)/UCL Hospitals Joint Research Ethics Committee (REC 03/N008). All subjects provided informed written consent. SNP genotyping was carried out by amplifying the SNP with FlashTaq 2X Master Mix, before sequencing by GeneWiz, Inc. (South Plainfield, NJ). Primer sequences for amplification were as follows: rs362331 forward: GGGCATTCTGTGACTCGGTA; rs362331 reverse: GATAGGAACCCACCGTTCAT; rs362273 forward: AGTGACAAATCCCCAAGACC; rs362273 reverse: GAGCTTTTCTCCTGGGTGTG; rs362307 forward: GCTCTGCTCGCTCTCCAG; rs362307 reverse: GCAGAGACACGCACGTTG. SNP linkage to *mHTT* was performed using the SNP linkage by circularization technique, using previously published methodology¹⁵. Details of the subject cohort used for each experiment are contained in Supplementary Table S1.

HTT suppression. GeRPs were synthesised and loaded with siRNA according to previously published methodology¹⁸. siRNA guide sequences were as follows: nonsense: 5'-pUUUCGAAGUACUCAGCGUGAG-3'; anti-total *HTT*: 5'-pUUCACAGCUUUUCCAGGGUC-3'; rs362331 anti-C: 5'-pUUCACAGUGGAGGAGGGAGC-3'; rs362331 anti-U: 5'-pGUACACAGUAGAGGAGGAGC-3'; rs362273 anti-A: 5'-pUUUGAUUUGUAGCAGCAGCUU-3'; rs362273 anti-G: 5'-pUUUGCUCUGCAGCAGCAGCUU-3'; rs362307 anti-U: 5'-pCACACGGGCACAGACUCCAA-3'. The siRNA Sequence Probability-of-Off-Targeting Reduction (siSPOTR) algorithm (<https://sispotr.icts.uiowa.edu/sispotr/index.html>) was used to identify additional transcripts with the potential for off-target suppression. Genes with an individual transcript Probability of Off-Target Score (tPOTS) ≥ 0.2 were then analysed using the GO annotation enrichment analysis tool (<http://www.geneontology.org/>) to identify overlapping biological processes. A complete list of siSPOTR results and GO pathways for the rs362331 siRNAs is contained in Supplementary Data S1.

To test the siRNAs, monocytes were isolated from peripheral blood samples by density centrifugation and magnetic cell sorting, before differentiation into macrophages as previously described¹⁴. Transfection was carried out on day three of the differentiation protocol by changing to fresh media containing GeRPs at a 10:1 particle to cell ratio. GeRPs were removed after 24 h by complete media change; this protocol achieves 90% transfection efficiency. Huntingtin mRNA and protein levels were then measured after a further 48 h in culture.

Allele-specific qPCR. Custom TaqMan[®] probes were designed for each SNP allele, before TaqMan[®] Gene Expression Master Mix was used to analyse allele-specific *HTT* expression. Primers used for allele-specific qPCR were as follows: rs362331 forward: CTGGAGCGTGGTCTCCTCCACA; rs362331 reverse: GTGTGTTTGGATCTACTTCCTCC; rs362273 forward: CTACTACAGGTGCCCTCATCAG; rs362273 reverse: GTGACGAAGGTGCAGGGGCGTC; rs362307 forward: ATGGTGGGAGAGACTGTGAGGC; rs362307 reverse: ATGGCAGAGACACGCACGTTGC. Probes used for allele-specific qPCR were as follows: rs362331 C: 6FAM-TCCCTCATCCACTGTGTGC-MGBNFQ; rs362331 T: VIC-TCCCTCATCTACTGTGTGC-MGBNFQ; rs362273 A: 6FAM-GCTGCTGCTACAGATCAAC-MGBNFQ; rs362273 G: VIC-GCTGCTGCTGAGATCAAC-MGBNFQ; rs362307 C: 6FAM-TGGAAGTCTGCGCCCTTGTG-MGBNFQ; rs362307 U: VIC-TGGAAGTCTGCGCCCTTGTG-MGBNFQ. Primers and probes were used at final concentrations of 500 nM and 150 nM respectively. Thermal cycling conditions were as follows: 50 °C for 2 min and 95 °C for 10 min followed by forty cycles of 95 °C for 15 s and either 65 °C (for rs362331 and rs362273) or 67.5 °C (for rs362307) for 1 min. *GAPDH* and *ACTB* were used as reference genes.

HTT protein quantification assays. Total (polyQ-independent) and mHTT (polyQ-dependent) protein levels were measured by Meso Scale Discovery (MSD) assays using a protocol adapted from published methods¹⁹. 2B7 and biotinylated-4C9 were used as the antibody pair for detection of total HTT²⁰, while 2B7 and biotinylated MW1 were used as the antibody pair for detection of mHTT²¹. Readings were normalised to total protein content of the sample as measured by BCA assays.

MSD cytokine assays. Monocyte-derived macrophages were stimulated by changing to fresh media containing 2 µg/ml LPS and 10 ng/ml IFN γ 72 h after GeRP treatment. After a further 24 h the supernatants were analysed using the V-PLEX Human Proinflammatory Panel II (4-Plex) Kit. IL-1 β was not included in the analysis as previous work has shown that its production is not upregulated in HD myeloid cells¹⁴. Readings were normalised to total protein content of the sample as measured by BCA assays.

Statistical analysis. Statistical analysis was carried out using GraphPad Prism 6 (GraphPad). Analysis of mRNA knockdown was performed using two-way ANOVAs with Bonferroni post-hoc multiple comparison testing. Protein knockdown and cytokine profiling experiments were analysed using one-way ANOVAs with Tukey post-hoc multiple comparison testing. All error bars represent standard error of the mean.

References

- Ross, C. A. & Tabrizi, S. J. Huntington's disease: from molecular pathogenesis to clinical treatment. *Lancet Neurol.* **10**, 83–98 (2011).
- Boudreau, R. L. *et al.* Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. *Mol Ther.* **17**, 1053–1063 (2009).
- Drouet, V. *et al.* Sustained effects of nonallele-specific Huntington silencing. *Ann Neurol.* **65**, 276–285 (2009).
- Kordasiewicz, H. B. *et al.* Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. *Neuron.* **74**, 1031–1044 (2012).
- Grondin, R. *et al.* Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. *Brain.* **135**, 1197–1209 (2012).
- Wang, G., Liu, X., Gaertig, M. A., Li, S. & Li, X. J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. *Proc Natl Acad Sci USA* **113**, 3359–3364 (2016).
- Sah, D. W. & Aronin, N. Oligonucleotide therapeutic approaches for Huntington disease. *J Clin Invest.* **121**, 500–507 (2011).
- Pfister, E. L. *et al.* Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. *Curr Biol.* **19**, 774–778 (2009).
- Carrroll, J. B. *et al.* Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. *Mol Ther.* **19**, 2178–2185 (2011).
- Østergaard, M. E. *et al.* Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. *Nucleic Acids Res.* **41**, 9634–9650 (2013).
- Drouet, V. *et al.* Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells. *PLoS One* **9**, e99341 (2014).
- Träger, U. *et al.* Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. *Neurobiol Dis.* **73C**, 388–398 (2014).
- Miniarikova, J. *et al.* Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease. *Mol Ther Nucleic Acids.* **5**, e297 (2016).
- Träger, U. *et al.* HTT-lowering reverses Huntington's disease immune dysfunction caused by NF κ B pathway dysregulation. *Brain.* **137**, 819–833 (2014).
- Liu, W. *et al.* Linking SNPs to CAG repeat length in Huntington's disease patients. *Nat Methods.* **5**, 951–953 (2008).
- Khoshnan, A. *et al.* Activation of the I κ B kinase complex and nuclear factor- κ B contributes to mutant huntingtin neurotoxicity. *J Neurosci.* **24**, 7999–8008 (2004).
- Miller, J. R. *et al.* RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. *Hum Mol Genet.* **25**, 2893–2904 (2016).
- Soto, E. R., Caras, A. C., Kut, L. C., Castle, M. K. & Ostroff, G. R. Glucan particles for macrophage targeted delivery of nanoparticles. *J Drug Deliv.* **2012**, 143524(2012).
- Macdonald, D. *et al.* Quantification assays for total and polyglutamine-expanded huntingtin proteins. *PLoS One* **9**, e96854 (2014).
- Baldo, B. *et al.* TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington's disease. *Chem Biol.* **19**, 264–275 (2012).
- Ko, J., Ou, S. & Patterson, P. H. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. *Brain Res Bull.* **56**, 319–329 (2001).

Acknowledgements

We thank the patients who donated samples, and the staff of the multidisciplinary Huntington's disease clinic at the National Hospital for Neurology and Neurosurgery, London. We also thank the late Dr. Paul Patterson for the MW1 antibody. This study was funded by the Medical Research Council, Rosetrees Trust and National Institutes of Health (NIH 38194).

Author Contributions

J.R.C.M., E.L.P., U.T., G.O., N.A. and S.J.T. conceived and designed the project. J.R.C.M., E.L.P., W.L., R.A., L.A.K., K.L., S.D., D.M., G.O., N.A. and S.J.T. collected, analysed, and interpreted the data. J.R.C.M., R.A. and S.J.T. wrote the paper.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Miller, J. R. C. *et al.* Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells. *Sci. Rep.* **7**, 46740; doi: 10.1038/srep46740 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017